A reAl-World Evidence Study Using Alberta Population Based Data to Describe Treatment Patterns for Metastatic castRation sENsitivE proState Cancer patientS (AWARENESS)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Bayer
- Enrollment
- 960
- Locations
- 1
- Primary Endpoint
- Descriptive summary of patient characteristics by cohort
Study Overview
Brief Summary
This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied.
Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has spread to other parts of the body, and still responds to treatment that lowers testosterone levels.
Cancer is a condition in which the body cannot control the growth of cells. The extra cells can form tumors in organs or other parts of the body. If tumors form in the prostate, male hormones (androgens) can sometimes help the cancer spread and grow. The main hormone that does this is called testosterone and is mainly made in the testicles. Men with prostate cancer can have treatments to try to lower the levels of testosterone in the body. One possible treatment is surgery to remove the testicles. Another option is taking treatments to lower the levels of testosterone in the body. These are called androgen deprivation therapy (ADT). In men with mCSPC, ADT can help to stop the cancer from growing and spreading. Men with mCSPC can also receive "treatment intensification". This means that they receive ADT as well as other treatments for their prostate cancer. Other studies that looked at treatment of mCSPC in Canada have found that most men with mCSPC do not receive treatment intensification.
In this study, the researchers want to collect more data about the men who had mCSPC and the types of treatment they received for their mCSPC. The researchers will look at the health information of adult men in Alberta, Canada who had at least 1 dose of treatment for their mCSPC between January 2016 and December 2020 or earlier.
The study will first look at the health information of men whose cancer had metastasized or spread to other parts of the body, beyond the prostate, at the time they were diagnosed with prostate cancer.
And later, if feasible to do, the study may also look at the health information from men who were diagnosed with prostate cancer that was limited to the prostate, and over time spread to other parts of the body.
The researchers will collect information from databases, a census, and pharmacy records. This will help the researchers learn more about:
- whether the men received ADT alone, or ADT with treatment intensification
- additional information about the men, including their age, income, level of education, residential area (urban or rural) and the more information about the treatments received
- how the men's symptoms affected their daily lives
- how severe the men's cancer was
- changes in laboratory values as markers for changes to the blood, liver, kidney, bone or other organs
- need for additional treatment
- where the men's cancer may have spread to in other parts of the body.
There will be no required visits with a study doctor or required tests in this study since it's reviewing patient data from the past.
The researchers will collect this information for about 7 months. The entire study will take about 10 months to finish.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male patients
- •Diagnosed with mCSPC
- •Residents of Alberta, Canada
- •Initiating ADT with or without treatment intensification from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff
Exclusion Criteria
- •There are no formal exclusion criteria in order to capture real-world utilization of ADT with or without treatment intensification
Arms & Interventions
mCSPC patients in the province of Alberta
mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
Intervention: ADT (Eligard®*) with or without treatment intensification (Drug)
Outcomes
Primary Outcomes
Descriptive summary of patient characteristics by cohort
Time Frame: Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff
Secondary Outcomes
- Change in percentage of patients within each treatment cohort by year(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Overall survival(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Percentage of patients that died due to cancer(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Percentage of patients that received subsequent life-prolonging therapies (LPT)(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Attrition rate for each line of therapy(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Total incidence (number) of hospitalizations(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)
- Total incidence (number) of emergency department visits(Retrospective analysis from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff)